Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC) (GALOCEAN)
A Prospective, Non-interventional, Multi-country Cohort Study of the Effectiveness and Safety of Filgotinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Alfasigma Medical Medical Information
- Phone Number: 00800 7878 1345
- Email: medicalinfo@alfasigma.com
Study Locations
-
-
-
Graz, Austria, 8036
- LKH - Universitätsklinikum Graz
-
Klagenfurt, Austria, 9020
- Klinikum Klagenfurt Am Worthersee
-
Sankt Veit an der Glan, Austria, 9300
- KH der Barmherzigen Brüder St.Veit an der Glan
-
Vienna, Austria, 1090
- AKH - Medizinische Universität Wien
-
-
-
-
-
Bonheiden, Belgium, 2820
- Imeldaziekenhuis
-
Brussels, Belgium, 1070
- Cliniques Universitaires de Bruxelles Hopital Erasme
-
Brussels, Belgium, 1000
- CHU Saint-Pierre
-
Edegem, Belgium, 2650
- UZA
-
Ghent, Belgium, 9000
- AZ Sint-Lucas
-
Ghent, Belgium, 9000
- Universitair Ziekenhuis Gent
-
Ghent, Belgium, 9000
- AZ Maria Middelares
-
Heusden-Zolder, Belgium, 3550
- Sint-Franciscus ziekenhuis
-
Leuven, Belgium, 3000
- UZ Leuven
-
Liège, Belgium, 4000
- CHU de Liege
-
Liège, Belgium, 4000
- Clinique CHC MontLégia
-
Ostend, Belgium, 8400
- AZ Damiaan
-
-
-
-
-
Amiens, France, 80000
- CHU Amiens - Hopital Sud
-
Besançon, France, 25000
- Hôpital Jean Minjoz
-
Clichy, France, 92200
- Clinique Abroise Paré
-
Grenoble, France, 38043
- CHU de Grenoble - Hôpital Nord
-
Lille, France, 59000
- CHU Lille - Hôpital Claude Huriez
-
Montpellier, France, 34090
- CHU Montpellier- Hôpital Saint Eloi
-
Nancy, France, 54000
- CHRU de Nancy
-
Nantes, France, 44093
- CHU Nantes - Hôtel Dieu
-
Paris, France, 75010
- Hôpital Saint-Louis
-
Pessac, France, 33604
- CHU Bordeaux - Hôpital Haut-Lévêque
-
Pierre-Bénite, France, 69495
- Centre Hospitalier LYON SUD
-
Saint-Etienne, France, 42055
- CHU Saint Etienne - Hôpital Nord
-
Toulouse, France, 31059
- Hopital Rangueil
-
-
-
-
-
Amberg, Germany, 92224
- Klinikum St. Marien Amberg
-
Dachau, Germany, 85221
- Medizinisches Versorgungszentrum Dachau
-
Hamburg, Germany, 22041
- Fachinternistische Schwerpunktpraxis
-
Heidelberg, Germany, 69115
- Praxis fur Gastroenterologie
-
Kiel, Germany, 24105
- Universitaetsklinikum Schleswig-Holstein
-
Leipzig, Germany, 04103
- Universitätsklinikum Leipzig AöR
-
Münster, Germany, 48159
- Gastro Campus Research GbR
-
Remscheid, Germany, 42859
- Magen-Darm-Zentrum Remscheid
-
Tübingen, Germany, 72076
- Universitatsklinikum Tubingen
-
-
Bavaria
-
Grünwald, Bavaria, Germany, 82031
- Synesis GmbH
-
-
-
-
-
Cork, Ireland, T12 DFK4
- Cork University Hospital
-
Dublin, Ireland, D04 T6F4
- St Vincent's University Hospital
-
Dublin, Ireland, D09 A0HK
- Beaumont Hospital
-
-
-
-
-
Milan, Italy, 20122
- Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
-
Milan, Italy, 20157
- ASST Fatebenefratelli Sacco
-
Negrar, Italy, 37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
Palermo, Italy, 90146
- Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello
-
Rozzano, Italy, 20089
- IRCCS Istituto Clinico Humanitas
-
Torino, Italy, 10128
- Ospedale Mauriziano Umberto I
-
-
Italia
-
Bari, Italia, Italy, 70013
- Azienda Ospedaliera Saverio De Bellis - Castellana Grotte
-
Milan, Italia, Italy, 20132
- IRCCS Ospedale San Raffaele ,Via Olgettina 60
-
Pisa, Italia, Italy, 56124
- Azienda Ospedaliero Universitaria Pisana - Cisanello
-
-
-
-
-
Amsterdam, Netherlands, 1091 AC
- Onze Lieve Vrouwe Gasthuis
-
Amsterdam, Netherlands, 1105 AZ
- Amsterdam UMC (AMC)
-
Geleen, Netherlands, 6162 BG
- Zuyderland Medisch Centrum - Sittard-Geleen
-
Nijmegen, Netherlands, 6525 GA
- Radboud UMC
-
Rotterdam, Netherlands, 3015 GD
- Erasmus MC
-
Rotterdam, Netherlands, 3045 PM
- Franciscus Gasthuis
-
Tilburg, Netherlands, 5022 GC
- ETZ Elisabeth
-
Utrecht, Netherlands, 3584 CX
- UMC Utrecht
-
-
-
-
-
Bodø, Norway, 8092
- Nordlandsykehuset
-
Lørenskog, Norway, 1478
- Akershus universitetssykehus
-
Oslo, Norway, 0424
- Oslo University Hospital
-
Oslo, Norway, 1346
- Bærum Hospital , Gjettum
-
Tromsø, Norway, 9019
- Universitetssykehuset Nord-Norge
-
Trondheim, Norway, 7030
- St. Olav's University Hospital
-
-
-
-
Catalonia
-
Barcelona, Catalonia, Spain, 08025
- Hospital de La Santa Creu i Sant Pau
-
-
Spain
-
Badalona, Spain, Spain, 08916
- Hospital Universitari Germans Trias i Pujol
-
Barcelona, Spain, Spain, 08036
- Hospital Clinic de Barcelona, C/ Villarroel, 170
-
Las Palmas de Gran Canaria, Spain, Spain, 35012
- Hospital Universitario de Gran Canaria Dr. Negrín
-
Palma de Mallorca, Spain, Spain, 07120
- Hospital Universitari Son Espases
-
Santiago de Compostela, Spain, Spain, 15706
- Hospital Universitario de Santiago de Compostela
-
-
-
-
-
Belfast, United Kingdom, BT161RH
- The Ulster Hospital
-
Bury, United Kingdom, BL97TD
- Bury Care Organisation
-
Exeter, United Kingdom, EX2 5DW
- Royal Devon University Healthcare NHS Foundation Trust
-
Glasgow, United Kingdom, G514TF
- Queen Elizabeth University Hospital
-
Glasgow, United Kingdom, G40SF
- Glasgow Royal Infirmary
-
London, United Kingdom, SW170QT
- St George's Hospital
-
London, United Kingdom, NW10 7NS
- St Mark's Hospital, Central Middlesex, Acton Lane
-
Norwich, United Kingdom, NR47UY
- Norfolk and Norwich University Hospital
-
Oxford, United Kingdom, OX39DU
- John Radcliffe Hospital
-
Southampton, United Kingdom, SO16 6YD
- Southampton General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
1. Filgotinib-naïve participants with moderately or severely active UC as judged by the physician and starting filgotinib treatment according to local treatment guidelines, routine practices and product information.
Exclusion Criteria:
- Participation in any interventional or non-interventional study without prior approval from the medical leader. This does not preclude inclusion of participants enrolled to national registries.
- Participant is diagnosed with Crohn's disease.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Arm A: Filgotinib
Participants diagnosed with moderately or severely active UC taking filgotinib according to local treatment guidelines or routine clinical practice and product information.
|
Jyseleca
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment Persistence Rate at week 52.
Time Frame: Week 52
|
The persistence rate is defined as the percentage of participants who have continued filgotinib treatment since initiation.
|
Week 52
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline in HRQoL as measured by the Urgency Numeric Rating Scale (NRS)
Time Frame: Baseline, Weeks 10, 24, 52
|
Baseline, Weeks 10, 24, 52
|
|
Treatment Persistence Rate at weeks 10, 24, 76 and 104
Time Frame: Weeks 10, 24, 76 and 104
|
Weeks 10, 24, 76 and 104
|
|
Clinical Response Rate
Time Frame: Weeks 10, 24, 52, 76 and 104
|
Weeks 10, 24, 52, 76 and 104
|
|
Clinical Remission Rate
Time Frame: Weeks 10, 24, 52, 76 and 104
|
Weeks 10, 24, 52, 76 and 104
|
|
Change from Baseline in Health-Related Quality of Life (HRQoL) as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
Time Frame: Baseline, Weeks 10, 24, 52, 76 and 104
|
Baseline, Weeks 10, 24, 52, 76 and 104
|
|
Change from Baseline in HRQoL as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue score (FACIT-F)
Time Frame: Baseline, Weeks 10, 24, 52, 76 and 104
|
Baseline, Weeks 10, 24, 52, 76 and 104
|
|
Number of Participants with Adverse Events (AEs)
Time Frame: Up to 104 Weeks
|
Up to 104 Weeks
|
|
Number of Participants with Serious Adverse Events (SAEs)
Time Frame: Up To 104 Weeks
|
Up To 104 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Alfasigma Study Director, Alfasigma S.p.A.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GLPG0634-CL-425
- 105477 (Other Identifier: HMA-EMA Catalogues)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.